The Longevity Reality Radar
46 approaches, rated by evidence.

Retatrutide

Retatrutide (triple GIP/GLP-1/glucagon agonist). Diabetes & metabolic. Reviewed Jul 2026.

Top doses cut body weight by about 28 to 30% in trials, but outcome trials are still running and it is not approved.

Stage
Phase 3
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
B
weight-loss trials
Randomised human data on surrogate markers, or consistent large cohorts. How grades work.

What it is

A next-generation incretin hitting three metabolic receptors at once — the most potent weight-loss agent yet reported.

The evidence

Phase 2 / interim Phase 3: highest-dose participants lost ~28–30% of body weight over ~80 weeks (avg ~70 lbs), with ~45% losing 30%+. Phase 3 outcome trials ongoing.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

  • Coverage, not a sourcex.com

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Diabetes & metabolic

All 3 in Diabetes & metabolic.

  • Semaglutide and tirzepatideGrade A, outcome RCTs. Approved.Large outcome trials show fewer cardiovascular events and kidney protection, with open questions on muscle loss and lifelong use.
  • Stem-cell islets for type 1 diabetesGrade C, 12-patient early trial. Phase 3.10 of 12 patients were off insulin at one year in an early trial, but it needs chronic immunosuppression and Phase 3 results are not out.